RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+10.96%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$783M
AUM Growth
+$783M
(+12%)
Cap. Flow
+$41.9M
Cap. Flow
% of AUM
5.35%
Top 10 Holdings %
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$14.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$12.9M |
| 3 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$11.6M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$10.1M |
| 5 |
Glaukos
GKOS
|
$9.98M |
Top Sells
| 1 |
Pfizer
PFE
|
$15M |
| 2 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$13.8M |
| 3 |
Zimmer Biomet
ZBH
|
$11.6M |
| 4 |
NovoCure
NVCR
|
$10.9M |
| 5 |
Biogen
BIIB
|
$8.3M |
Sector Composition
| 1 | Healthcare | 89.3% |
| 2 | Financials | 1.39% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.13% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $38.1M | 4.87% | 3,006,862 +584,772 | +24% | +$7.41M |
|
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $27.4M | 3.49% | 180,000 +84,987 | +89% | +$12.9M |
|
3
Exelixis
EXEL
$10.1B
| $25.4M | 3.25% | 1,050,000 | – | – |
|
|
ABMD
4
DELISTED
Abiomed Inc
ABMD
| $23.6M | 3.02% | 140,238 +34,088 | +32% | +$5.75M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $23.1M | 2.96% | 165,000 +11,000 | +7% | +$1.54M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $22.2M | 2.83% | 152,000 +10,000 | +7% | +$1.46M |
|
|
7
Glaukos
GKOS
$5.5B
| $21.4M | 2.73% | 647,796 +302,346 | +88% | +$9.98M |
|
8
Nektar Therapeutics
NKTR
$568M
| $20.8M | 2.65% | 866,194 +71,194 | +9% | +$1.71M |
|
|
AGN
9
DELISTED
Allergan plc
AGN
| $20.5M | 2.62% | 100,000 +48,000 | +92% | +$9.84M |
|
|
ADMS
10
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $19.4M | 2.47% | 915,000 +546,834 | +149% | +$11.6M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $18.6M | 2.38% | 1,179,900 +346,746 | +42% | +$5.47M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $16.7M | 2.14% | 179,949 -9,351 | -5% | -$870K |
|
13
Medtronic
MDT
$119B
| $16.7M | 2.13% | 214,115 +23,000 | +12% | +$1.79M |
|
14
UnitedHealth
UNH
$281B
| $16.6M | 2.13% | 85,000 -5,000 | -6% | -$979K |
|
|
PTLA
15
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $16.1M | 2.05% | 297,400 +186,595 | +168% | +$10.1M |
|
16
Esperion Therapeutics
ESPR
$448M
| $15.6M | 2% | 311,803 -51,544 | -14% | -$2.58M |
|
|
ESRX
17
DELISTED
Express Scripts Holding Company
ESRX
| $15.5M | 1.98% | 245,000 +89,000 | +57% | +$5.64M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.5M | 1.85% | +569,491 | New | +$14.5M |
|
19
Incyte
INCY
$16.5B
| $13.4M | 1.71% | 115,000 -25,046 | -18% | -$2.92M |
|
|
20
NovoCure
NVCR
$1.38B
| $13.2M | 1.69% | 666,528 -549,786 | -45% | -$10.9M |
|
21
Gilead Sciences
GILD
$140B
| $12.6M | 1.61% | 155,551 -101,365 | -39% | -$8.21M |
|
22
AbbVie
ABBV
$372B
| $12.4M | 1.59% | 140,000 +5,000 | +4% | +$444K |
|
23
Jazz Pharmaceuticals
JAZZ
$7.75B
| $12.4M | 1.59% | 85,000 -20 | -0% | -$2.93K |
|
|
NVRO
24
DELISTED
NEVRO CORP.
NVRO
| $11.8M | 1.51% | 130,000 -25,118 | -16% | -$2.28M |
|
25
Centene
CNC
$14.3B
| $10.6M | 1.36% | 110,000 +10,000 | +10% | +$968K |
|